eccogene glp 1 obtains exclusive license from AstraZeneca to develop and sell ECC5004, a GLP-1 receptor agonist for cardio-metabolic diseases Non‐clinical and first‐in‐human characterization of
Pay in 4 interest-free payments of $6.64 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Nov 21 - Nov 26























